Newly Granted European Composition of Matter Patent Extends Exclusive Protection for VBL Therapeutics’ Lead Drug Candidate VB-111 until October 2033

On October 23, 2018 VBL Therapeutics (NASDAQ:VBLT), reported the issuance by the European Patent Office (EPO) of Patent No. 2908865, a composition of matter patent which covers VB-111, VBL’s lead drug candidate (Press release, VBL Therapeutics, OCT 23, 2018, View Source [SID1234530057]). The patent provides intellectual property protection for VB-111 in Europe until October 2033, before any potential extension. The patent further strengthens the VB-111 intellectual property portfolio, which comprises multiple granted patents including composition of matter patents in the US, Japan, China and additional countries.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"VBL is focused on continually innovating and advancing cancer treatments," said Dror Harats, M.D., CEO of VBL Therapeutics. "This latest patent grant by the EPO further reinforces our commitment to excellent research and innovation as well as to protecting our lead candidate, VB-111, which is currently being investigated in our OVAL Phase 3 trial in platinum-resistant ovarian cancer."

About Ofranergene Obadenovec (VB-111)
VB-111, a potential first-in-class anticancer therapeutic candidate, is the Company’s lead oncology product currently being studied in a Phase 3 trial for ovarian cancer. VB-111 has received orphan drug designation in both the US and Europe, and fast track designation in the US for prolongation of survival in patients with rGBM. In addition, VB-111 successfully demonstrated proof-of-concept and survival benefit in Phase 2 clinical trials in radioiodine-refractory thyroid cancer and recurrent platinum-resistant ovarian cancer. VB-111 has received an Orphan Designation for the treatment of ovarian cancer by the European Medicines Agency (EMA).